Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biyoderm
- Development stage
- Unknown
- Lead developer
- Arthro-Kinetics
- Administration
- Topical
01
Overview
Biyoderm is a biological wound dressing developed by Ars Arthro, primarily composed of bovine-derived Type I collagen. It functions as an acellular dermal matrix or scaffold that facilitates tissue regeneration by providing a structural framework for cell migration, adhesion, and proliferation. It is indicated for the management of various wound types, including chronic wounds (such as diabetic foot ulcers and pressure ulcers), partial and full-thickness wounds, and surgical sites. By mimicking the natural extracellular matrix, Biyoderm supports the body's healing processes and promotes the formation of new granulation tissue. It is CE marked and marketed for use in regenerative medicine and wound care.
- Brand names
- Biyoderm
Beyond the preview
Go deeper on Biyoderm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biyoderm.